SkIn, Muscle and Bone Aging Determinants in HIV Infected-patients. (SIMBAD)

University Hospital of Bordeaux

Status: Completed

Conditions: HIV-1-infection; Marker; Structural

Treatments: Procedure: DXA (dual-energy x-ray absorptiometric) measurement

Study type: Interventional

Funder types: Other

Identifiers

NCT04067219

CHUBX 2011/02

Details and patient eligibility

About

this study consists of the study of markers of skin, muscular, neurocognitive and bone aging in HIV infected adults and to compare the frequency of these signs to the general population of same gender and age.

Full description

Nowadays, the elevated frequency of cancers as well as cardiovascular, neurocognitive and bone diseases seems to denote a process of accelerated aging in the treated HIV-infected population of western countries, who are 40 to 50 years old in median. Markers of age-related alterations should be compared to the distribution among the general population whenever possible, to disentangle the effect of HIV and "normal" ageing or ageing due to other conditions. Common mechanisms should be better understood, more specifically those related to the impact of tobacco, antiretroviral treatments, and nutritional components. For markers of skin, muscle, neurocognitive function and bone ageing, the distribution of the general population is available and, in addition, alteration of these markers might have common mechanisms, such as insufficiency in 25 hydroxy vitamin D or nutritional parameters. Therefore, a joint study of these three organs seems particularly relevant.

This aim is to study markers of skin, muscular, neurocognitive and bone aging in HIV infected adults and to compare the frequency of these signs to the general population of same gender and age.

Enrollment: 246 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• HIV-1 infected patients included in the TISSOS-VIH substudy of the ARNS CO3 Aquitaine Cohort or who had a DXA measurement of the lumbar spine, femoral neck, and total body between 2004 and 2011 at the University Hospital of Bordeaux,
• > 18 years
• Affiliated to the medical insurance
• Having had at least one DXA measurement prior to the SIMBAD study visit
• Written informed consent for the SIMBAD study

Exclusion criteria

• Hepatitis C virus co-infection
• Pregnancy

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

246 participants in 1 patient group

Single arm

Experimental group

Description:

HIV-1 infected patients

Treatment:

Procedure: DXA (dual-energy x-ray absorptiometric) measurement